Enovis Reports Q1 2026 Earnings With Mixed Performance Across Segments
Enovis (ENOV) reported first-quarter earnings for fiscal year 2026 with mixed results across its segments. The company achieved $589 million in sales, up 5% on a reported basis but faced headwinds from fewer selling days and the Dr. Comfort divestiture. Organic revenue growth was 3%, driven by strong performance in Recon products.
Topics: adjusted_gross_margin ebitda organic_growth revenue segments_performance